Authors: Emile Verhulst, Michelle De Bruyn, Pascale Berckmans, Yani Sim, Koen Augustyns, Isabel Pintelon, Maya Berg, Pieter Van Wielendaele, Anne‐Marie Lambeir, Yann G.‐J. Sterckx, Inge Nelissen, Ingrid De Meester
Published: 2025-03-17
DOI: 10.1002/jev2.70061
Source: Full article
ABSTRACTHuman transmembrane serine protease 2 (TMPRSS2) has garnered substantial interest due to its clinical significance in various pathologies, notably its pivotal role in viral entry into host cells. The development of effective strategies to target TMPRSS2 is a current area of intense research and necessitates a consistent source of active TMPRSS2 with sufficient stability. Here, we comprehensively characterised human seminal‐fluid extracellular vesicles (SF‐EVs, also referred to as prostasomes), bearing a native source of surface‐exposed, enzymatically active TMPRSS2 as demonstrated by high‐sensitivity flow cytometry and a fluorometric activity assay. Additionally, we recombinantly produced human TMPRSS2 ectodomain in mammalian cells adopting a directed activation strategy. We observed comparable catalytic parameters and inhibition characteristics for both native SF‐EV‐associated and recombinant TMPRSS2 when exposed to serine protease inhibitor Nafamostat mesylate. Leveraging these findings, we developed a robust in vitro biochemical assay based on these SF‐EVs for the screening of TMPRSS2‐targeting compounds. Our results will accelerate the discovery and advancement of efficacious therapeutic approaches targeting TMPRSS2 and propel further exploration into the biological role of SF‐EV‐associated active TMPRSS2.